Holiday Greetings & Metrics from the MSK Library

The end of year is rapidly approaching and the MSK Library team has been very busy supporting and collaborating with our user community. To gain a sense of what we’ve been up to this year, take a moment to explore our new Library Dashboard, with a fresh look and feel, outlining the team’s activities via metrics. The information presented represents a snapshot of the work we do.

These metrics focus on a variety of services and resources such as:
1. literature search and document delivery requests; 
2. class attendance;
3. content usage for our digital journal and book collections;
4. website traffic;
5. our new FAQs section, designed to help users find quick answers to our most popular client questions;
6. Synapse and the increasing number of MSK authors and their publications;
7. research data management and how we are tracking the MSK Data Catalog views, where MSK researchers are depositing their data sets, and the growing interest in data management plans;
8. our quarterly virtual event, Advancing Authorship Series;
9.  and the SKOAP Fund request submissions we are tracking for authors who need financial support for article processing charges.

We also continued to promote our in-person and Virtual Library Services in support of incoming client requests and encouraged our user community to use our chat feature on the library website as a way to obtain immediate help. 

However you celebrate, I hope you find moments of joy and happiness this holiday season to lift your spirit and restore your energy for 2024. Wishing a very Happy New Year to all!

Cheers,
Donna Gibson
Director, Library Services

MSK Library Holiday Hours

Please note, beginning next week MSK Library will be operating on our holiday hours schedule:

Monday, December 18 – Friday, December 22: 8:30AM – 5:00PM
Monday, December 25: Closed
Tuesday, December 26 – Friday, December 29: 8:30AM – 5:00PM
Monday, January 1: Closed

Wishing the entire MSK community a peaceful and restful holiday season. 

Epcoritamab-bysp and FDA’s Breakthrough Therapy Designation

The FDA just granted Breakthrough Therapy Designation to Epcoritamab-bysp (brand name is Epkinly) for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL).

The decision to grant BTD was supported by the results from the clinical trial NCT03625037, “First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1).
Obtaining Breakthrough Therapy Designation helps facilitate the development of new drugs and treatment options for patients.

Based on the same clinical trial, the FDA approved epcoritamab for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma in May 2023. In the podcast “Oncology Nursing News: The Vitals” Laura Zitella, a nurse at UCSF Health, discusses the newly approved epcoritamab-bysp for DLBCL.

The estimated study completion date of the clinical trial NCT03625037 is April 2024.